ENG 繁 简
E Fund (HK) Solactive Biopharma Select Index ETF
03186 HKD
Important Notes Fund Information Portfolio Allocation Performance Distribution History Announcements Notices Documents
Important Notes

1) E Fund (HK) Solactive Biopharma Select Index ETF (the “Sub-Fund”) is a sub-fund of E Fund ETFs Trust, an umbrella unit trust established under Hong Kong law. The Sub-Fund is a passively-managed ETF falling within Chapter 8.6 of the Code on Unit Trusts and Mutual Funds issued by the Securities and Futures Commission (the “SFC”). Units of the Sub-Fund (the “Units”) are traded on The Stock Exchange of Hong Kong Limited (the “SEHK”) like stocks. The investment objective is to provide investment results that, before fees and expenses, closely correspond to the performance of the Solactive Biopharma Select Index (the “Index”).
2) Investment involves risks. The Fund is subject to a) Investment risk, b) Equity market risk, c) New Index risk, d) Geographical concentration risk, e) Political, economic and social risks in mainland China, f) Biopharmaceuticals sector concentration risk, g) Risk associated with small-capitalisation / mid-capitalisation companies, h) Securities lending transactions risk, i) Trading differences risk, j) Passive investments risk, k) Trading risk, l) Tracking error risk, m) Currency risk, n) Distribution out of/effectively out of capital risk, o) Reliance on market maker risk, p) Termination risk. The value of the Sub-Fund can be volatile and may go down substantially. Investors may suffer losses.
4) Distributions of the Sub-Fund may be paid out of the capital of the Sub-Fund. Investors should note that payment of distributions out of capital amounts to a return or withdrawal of part of an investor’s original investment or from any capital gains attributable to that original investment and such distributions will result in an immediate reduction of the net asset value of the relevant units.
5) The Sub-Fund is traded on the exchange at market price, which may be different from its net asset value. Offering documents of the Sub-Fund can be obtained from https://www.efunds.com.hk/products/
6) The Index is a new index. The Index has minimal operating history by which investors can evaluate its previous performance. There can be no assurance as to the performance of the Index. The Sub-Fund may be riskier than other exchange traded funds tracking more established indices with longer operating history.
7) As the Sub-Fund's investments are concentrated in securities of Biopharmaceuticals companies in Hong Kong and the United States, and those companies may significantly be impacted by technological changes, increased governmental regulations and intense competition from competitors, the Sub-Fund is subject to sector and geographical concentration risks and its Net Asset Value is therefore likely to be more volatile than a broad-based fund.
8) You should not invest in the Sub-Fund unless the intermediary who sells it to you has explained to you that the Sub-Fund is suitable for you having regard to your financial situation, investment experience and objectives.
9) Investors should not invest in the Sub-Fund based on this document alone. Before making any investment decision, the investor should read the Sub-Fund’s offering documents carefully including the risk factors.

Disclaimer
Index Provider Disclaimer

Solactive AG (“Solactive") is the licensor of Solactive Biopharma Select Index (the “Index”). The financial instruments that are based on the Index are not sponsored, endorsed, promoted or sold by Solactive in any way and Solactive makes no express or implied representation, guarantee or assurance with regard to: (a) the advisability in investing in the financial instruments; (b) the quality, accuracy and/or completeness of the Index; and/or (c) the results obtained or to be obtained by any person or entity from the use of the Index. Solactive does not guarantee the accuracy and/or the completeness of the Index and shall not have any liability for any errors or omissions with respect thereto. Notwithstanding Solactive’s obligations to its licensees, Solactive reserves the right to change the methods of calculation or publication with respect to the Index and Solactive shall not be liable for any miscalculation of or any incorrect, delayed or interrupted publication with respect to the Index. Solactive shall not be liable for any damages, including, without limitation, any loss of profits or business, or any special, incidental, punitive, indirect or consequential damages suffered or incurred as a result of the use (or inability to use) of the Index.

E Fund HK Disclaimer

Unless otherwise stated, E Fund Management (Hong Kong) Co., Limited is the issuer of the content of this website. This website is neither an offer nor solicitation to purchase units of the fund. Applications for units may only be made on forms of application available with the Explanatory Memorandum.
Investment involves risk. Fund value may go up and down. Past performance is not indicative of future performance. Investors should read carefully the Explanatory Memorandum (including the risk factors) for the relevant risks associated with the investment in the fund before investing.
Distribution of the content herein may be restricted in certain jurisdictions. This website does not constitute the distribution of any information in any jurisdiction in which such distribution is unlawful. This website has not been reviewed by the Securities and Futures Commission of Hong Kong.
SFC authorization is not a recommendation or endorsement of a scheme nor does it guarantee the commercial merits of a scheme or its performance. It does not mean the scheme is suitable for all investors nor is it an endorsement of its suitability for any particular investor or class of investors.